Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 785

1.

Prospective validation of the PML risk biomarker l-Selectin and influence of natalizumab extended intervals.

Schwab N, Schneider-Hohendorf T, Pignolet B, Bucciarelli F, Scandella L, Ciron J, Biotti D, Lebrun-Frenay C, Mathey G, Clavelou P, Pelletier J, Ostkamp P, Meinl I, Windhagen S, Klotz L, Gross CC, Meuth SG, Deisenhammer F, Brassat D, Wiendl H; Best-MS Study Group.

Neurology. 2019 Aug 22. pii: 10.1212/WNL.0000000000008135. doi: 10.1212/WNL.0000000000008135. [Epub ahead of print] No abstract available.

PMID:
31439633
2.

Pretreatment anti-thyroid autoantibodies indicate increased risk for thyroid autoimmunity secondary to alemtuzumab: A prospective cohort study.

Ruck T, Schulte-Mecklenbeck A, Pfeuffer S, Heming M, Klotz L, Windhagen S, Kleinschnitz C, Gross CC, Wiendl H, Meuth SG.

EBioMedicine. 2019 Aug;46:381-386. doi: 10.1016/j.ebiom.2019.07.062. Epub 2019 Jul 29.

3.

Outcomes and prognosticators of stage 4 renal cell carcinoma with pathological T4 primary lesion using a large Canadian multi-institutional database.

Oake JD, Patel P, Lavallée LT, Lattouf JB, Saarela O, Klotz L, Moore RB, Kapoor A, Finelli A, Rendon RA, Kawakami J, So A, Drachenberg DE.

Can Urol Assoc J. 2019 Jul 23. doi: 10.5489/cuaj.5941. [Epub ahead of print]

PMID:
31348746
4.

Social Defeat Modulates T Helper Cell Percentages in Stress Susceptible and Resilient Mice.

Ambrée O, Ruland C, Zwanzger P, Klotz L, Baune BT, Arolt V, Scheu S, Alferink J.

Int J Mol Sci. 2019 Jul 17;20(14). pii: E3512. doi: 10.3390/ijms20143512.

5.

[Diagnostics and treatment of tuberculosis under immunotherapy for multiple sclerosis : Current status and recommendations in Germany].

Bittner S, Engel S, Lange C, Weber MS, Haghikia A, Luessi F, Korn T, Klotz L, Bayas A, Paul F, Heesen C, Stangel M, Wildemann B, Bergh FT, Tackenberg B, Trebst C, Warnke C, Linker R, Kerschensteiner M, Zettl U, Tumani H, Brück W, Meuth SG, Kümpfel T, Hemmer B, Wiendl H, Gold R, Zipp F.

Nervenarzt. 2019 Jul 11. doi: 10.1007/s00115-019-0760-0. [Epub ahead of print] Review. German.

PMID:
31297574
6.

Pleurectomy/decortication and hyperthermic intrathoracic chemoperfusion using cisplatin and doxorubicin for malignant pleural mesothelioma.

Klotz LV, Lindner M, Eichhorn ME, Grützner U, Koch I, Winter H, Kauke T, Duell T, Hatz RA.

J Thorac Dis. 2019 May;11(5):1963-1972. doi: 10.21037/jtd.2019.04.93.

7.

Apalutamide for Metastatic, Hormone-Responsive Prostate Cancer.

Klotz L.

N Engl J Med. 2019 Jul 4;381(1):84-86. doi: 10.1056/NEJMe1905891. No abstract available.

PMID:
31269371
8.

Re: Active Surveillance of Prostate Cancer is a Viable Option for Men Younger than 60 Years.

Salari K, Kuppermann D, Preston MA, Dahl DM, Barrisford GW, Efstathiou JA, Blute ML, Vesprini D, Loblaw A, Zietman AL, Klotz L, Feldman AS.

J Urol. 2019 Jun 4:101097JU0000000000000363. doi: 10.1097/JU.0000000000000363. [Epub ahead of print] No abstract available.

PMID:
31163004
9.

[Interventional treatment of tracheopleural and bronchopleural fistulas].

Klotz LV, Eberhardt R, Herth FJF, Winter H.

Chirurg. 2019 Jun 3. doi: 10.1007/s00104-019-0977-2. [Epub ahead of print] Review. German.

PMID:
31161248
10.

Club cells form lung adenocarcinomas and maintain the alveoli of adult mice.

Spella M, Lilis I, Pepe MA, Chen Y, Armaka M, Lamort AS, Zazara DE, Roumelioti F, Vreka M, Kanellakis NI, Wagner DE, Giannou AD, Armenis V, Arendt KA, Klotz LV, Toumpanakis D, Karavana V, Zakynthinos SG, Giopanou I, Marazioti A, Aidinis V, Sotillo R, Stathopoulos GT.

Elife. 2019 May 29;8. pii: e45571. doi: 10.7554/eLife.45571.

11.

Advanced Androgen Blockage in Nonmetastatic Castration-resistant Prostate Cancer: An Indirect Comparison of Apalutamide and Enzalutamide.

Wallis CJD, Chandrasekar T, Goldberg H, Klotz L, Fleshner N, Satkunasivam R, Klaassen Z.

Eur Urol Oncol. 2018 Aug;1(3):238-241. doi: 10.1016/j.euo.2018.04.004. Epub 2018 May 15.

PMID:
31102627
12.

Contemporary approach to active surveillance for favorable risk prostate cancer.

Klotz L.

Asian J Urol. 2019 Apr;6(2):146-152. doi: 10.1016/j.ajur.2018.12.003. Epub 2018 Dec 15. Review.

13.

Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial.

Eichhorn F, Klotz LV, Bischoff H, Thomas M, Lasitschka F, Winter H, Hoffmann H, Eichhorn ME.

BMC Cancer. 2019 May 2;19(1):413. doi: 10.1186/s12885-019-5624-2.

14.

Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects.

Klotz L, Eschborn M, Lindner M, Liebmann M, Herold M, Janoschka C, Torres Garrido B, Schulte-Mecklenbeck A, Gross CC, Breuer J, Hundehege P, Posevitz V, Pignolet B, Nebel G, Glander S, Freise N, Austermann J, Wirth T, Campbell GR, Schneider-Hohendorf T, Eveslage M, Brassat D, Schwab N, Loser K, Roth J, Busch KB, Stoll M, Mahad DJ, Meuth SG, Turner T, Bar-Or A, Wiendl H.

Sci Transl Med. 2019 May 1;11(490). pii: eaao5563. doi: 10.1126/scitranslmed.aao5563.

PMID:
31043571
15.

Immune Cell Profiling of the Cerebrospinal Fluid Provides Pathogenetic Insights Into Inflammatory Neuropathies.

Heming M, Schulte-Mecklenbeck A, Brix T, Wolbert J, Ruland T, Klotz L, Meuth SG, Gross CC, Wiendl H, Meyer Zu Hörste G.

Front Immunol. 2019 Mar 21;10:515. doi: 10.3389/fimmu.2019.00515. eCollection 2019.

16.

Risks and risk management in modern multiple sclerosis immunotherapeutic treatment.

Klotz L, Havla J, Schwab N, Hohlfeld R, Barnett M, Reddel S, Wiendl H.

Ther Adv Neurol Disord. 2019 Apr 1;12:1756286419836571. doi: 10.1177/1756286419836571. eCollection 2019. Review.

17.

Real-world persistence and benefit-risk profile of fingolimod over 36 months in Germany.

Ziemssen T, Lang M, Tackenberg B, Schmidt S, Albrecht H, Klotz L, Haas J, Lassek C, Couto CA, Findlay JA, Cornelissen C; PANGAEA study group.

Neurol Neuroimmunol Neuroinflamm. 2019 Mar 7;6(3):e548. doi: 10.1212/NXI.0000000000000548. eCollection 2019 May.

18.

Active surveillance in intermediate risk prostate cancer.

Chandrasekar T, Herrera-Caceres JO, Klotz L.

Arch Esp Urol. 2019 Mar;72(2):157-166.

PMID:
30855017
19.

Re: Prostate Cancer-specific Mortality Across Gleason Scores in Black vs Nonblack Men.

Wallis CJD, Klotz L, Klaassen Z.

Eur Urol. 2019 Jun;75(6):1036-1037. doi: 10.1016/j.eururo.2019.02.019. Epub 2019 Feb 26. No abstract available.

PMID:
30819526
20.

Comprehensive clinical profiling of the Gauting locoregional lung adenocarcinoma donors.

Klotz LV, Courty Y, Lindner M, Petit-Courty A, Stowasser A, Koch I, Eichhorn ME, Lilis I, Morresi-Hauf A, Arendt KAM, Pepe M, Giopanou I, Ntaliarda G, Behrend SJ, Oplopoiou M, Gissot V, Guyetant S, Marchand-Adam S, Behr J, Kaiser JC, Hatz RA, Lamort AS, Stathopoulos GT.

Cancer Med. 2019 Apr;8(4):1486-1499. doi: 10.1002/cam4.2031. Epub 2019 Feb 25.

21.

Label-free molecular mapping and assessment of glycogen in C. elegans.

Cherkas A, Mondol AS, Rüger J, Urban N, Popp J, Klotz LO, Schie IW.

Analyst. 2019 Mar 25;144(7):2367-2374. doi: 10.1039/c8an02351d.

PMID:
30793720
22.

VLA-2 blockade in vivo by vatelizumab induces CD4+FoxP3+ regulatory T cells.

Breuer J, Schneider-Hohendorf T, Ostkamp P, Herich S, Rakhade S, Antonijevic I, Klotz L, Wiendl H, Schwab N.

Int Immunol. 2019 May 21;31(6):407-412. doi: 10.1093/intimm/dxz018.

PMID:
30783682
23.

Combining urinary DNA methylation and cell-free microRNA biomarkers for improved monitoring of prostate cancer patients on active surveillance.

Zhao F, Vesprini D, Liu RSC, Olkhov-Mitsel E, Klotz LH, Loblaw A, Liu SK, Bapat B.

Urol Oncol. 2019 May;37(5):297.e9-297.e17. doi: 10.1016/j.urolonc.2019.01.031. Epub 2019 Feb 16.

PMID:
30777394
24.

Value of Increasing Biopsy Cores per Target with Cognitive MRI-targeted Transrectal US Prostate Biopsy.

Zhang M, Milot L, Khalvati F, Sugar L, Downes M, Baig SM, Klotz L, Haider MA.

Radiology. 2019 Apr;291(1):83-89. doi: 10.1148/radiol.2019180712. Epub 2019 Jan 29.

PMID:
30694165
25.

Discordance between testosterone measurement methods in castrated prostate cancer patients.

Rouleau M, Lemire F, Déry M, Thériault B, Dubois G, Fradet Y, Toren P, Guillemette C, Lacombe L, Klotz L, Saad F, Guérette D, Pouliot F.

Endocr Connect. 2019 Jan 1. pii: EC-18-0476. doi: 10.1530/EC-18-0476. [Epub ahead of print]

26.

Focal laser ablation as clinical treatment of prostate cancer: report from a Delphi consensus project.

van Luijtelaar A, Greenwood BM, Ahmed HU, Barqawi AB, Barret E, Bomers JGR, Brausi MA, Choyke PL, Cooperberg MR, Eggener S, Feller JF, Frauscher F, George AK, Hindley RG, Jenniskens SFM, Klotz L, Kovacs G, Lindner U, Loeb S, Margolis DJ, Marks LS, May S, Mcclure TD, Montironi R, Nour SG, Oto A, Polascik TJ, Rastinehad AR, De Reyke TM, Reijnen JS, de la Rosette JJMCH, Sedelaar JPM, Sperling DS, Walser EM, Ward JF, Villers A, Ghai S, Fütterer JJ.

World J Urol. 2019 Jan 22. doi: 10.1007/s00345-019-02636-7. [Epub ahead of print]

27.

Active Surveillance of Prostate Cancer is a Viable Option for Men Younger than 60 Years.

Salari K, Kuppermann D, Preston MA, Dahl DM, Barrisford GW, Efstathiou JA, Blute ML, Vesprini D, Loblaw A, Zietman AL, Klotz L, Feldman AS.

J Urol. 2019 Apr;201(4):721-727. doi: 10.1097/JU.0000000000000031.

PMID:
30664083
28.

Immunophenotyping of cerebrospinal fluid cells in ischaemic stroke.

Schulte-Mecklenbeck A, Kleffner I, Beuker C, Wirth T, Hartwig M, Schmidt-Pogoda A, Klotz L, Hansen W, Wiendl H, Meuth SG, Gross CC, Minnerup J.

Eur J Neurol. 2019 Jun;26(6):919-926. doi: 10.1111/ene.13909. Epub 2019 Feb 8.

PMID:
30659722
29.

ESTIMATING AND COMPARING CANCER PROGRESSION RISKS UNDER VARYING SURVEILLANCE PROTOCOLS.

Lange JM, Gulati R, Leonardson AS, Lin DW, Newcomb LF, Trock BJ, Carter HB, Cooperberg MR, Cowan JE, Klotz LH, Etzioni R.

Ann Appl Stat. 2018 Sep;12(3):1773-1795. doi: 10.1214/17-AOAS1130. Epub 2018 Sep 11.

30.

A Phase 1 Pilot Study of Preoperative Radiation Therapy for Prostate Cancer: Long-Term Toxicity and Oncologic Outcomes.

Glicksman R, Sanmamed N, Thoms J, Zlotta AR, Finelli A, van der Kwast T, Sweet J, Jewett M, Klotz LH, Rosewall T, Fleshner NE, Bristow RG, Warde P, Berlin A.

Int J Radiat Oncol Biol Phys. 2019 May 1;104(1):61-66. doi: 10.1016/j.ijrobp.2018.12.054. Epub 2019 Jan 6.

PMID:
30625410
31.

Interferon β-Mediated Protective Functions of Microglia in Central Nervous System Autoimmunity.

Scheu S, Ali S, Mann-Nüttel R, Richter L, Arolt V, Dannlowski U, Kuhlmann T, Klotz L, Alferink J.

Int J Mol Sci. 2019 Jan 7;20(1). pii: E190. doi: 10.3390/ijms20010190. Review.

32.

Combining Desmopressin and Docetaxel for the Treatment of Castration-Resistant Prostate Cancer in an Orthotopic Model.

Bass R, Roberto D, Wang DZ, Cantu FP, Mohamadi RM, Kelley SO, Klotz L, Venkateswaran V.

Anticancer Res. 2019 Jan;39(1):113-118. doi: 10.21873/anticanres.13086.

PMID:
30591447
33.

Dietary salt promotes ischemic brain injury and is associated with parenchymal migrasome formation.

Schmidt-Pogoda A, Strecker JK, Liebmann M, Massoth C, Beuker C, Hansen U, König S, Albrecht S, Bock S, Breuer J, Sommer C, Schwab N, Wiendl H, Klotz L, Minnerup J.

PLoS One. 2018 Dec 27;13(12):e0209871. doi: 10.1371/journal.pone.0209871. eCollection 2018.

34.

Oncologic and Functional Outcomes of Partial Gland Ablation with High Intensity Focused Ultrasound for Localized Prostate Cancer.

Bass R, Fleshner N, Finelli A, Barkin J, Zhang L, Klotz L.

J Urol. 2019 Jan;201(1):113-119. doi: 10.1016/j.juro.2018.07.040.

PMID:
30577402
35.

Can we predict cognitive decline after initial diagnosis of multiple sclerosis? Results from the German National early MS cohort (KKNMS).

Johnen A, Bürkner PC, Landmeyer NC, Ambrosius B, Calabrese P, Motte J, Hessler N, Antony G, König IR, Klotz L, Hoshi MM, Aly L, Groppa S, Luessi F, Paul F, Tackenberg B, Bergh FT, Kümpfel T, Tumani H, Stangel M, Weber F, Bayas A, Wildemann B, Heesen C, Zettl UK, Zipp F, Hemmer B, Meuth SG, Gold R, Wiendl H, Salmen A; German Competence Network Multiple Sclerosis (KKNMS).

J Neurol. 2019 Feb;266(2):386-397. doi: 10.1007/s00415-018-9142-y. Epub 2018 Dec 4.

36.

Selenium-binding protein 1 (SELENBP1) is a marker of mature adipocytes.

Steinbrenner H, Micoogullari M, Hoang NA, Bergheim I, Klotz LO, Sies H.

Redox Biol. 2019 Jan;20:489-495. doi: 10.1016/j.redox.2018.11.004. Epub 2018 Nov 10.

37.

Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation.

Pfeuffer S, Schmidt R, Straeten FA, Pul R, Kleinschnitz C, Wieshuber M, Lee DH, Linker RA, Doerck S, Straeten V, Windhagen S, Pawlitzki M, Aufenberg C, Lang M, Eienbroeker C, Tackenberg B, Limmroth V, Wildemann B, Haas J, Klotz L, Wiendl H, Ruck T, Meuth SG.

J Neurol. 2019 Jan;266(1):165-173. doi: 10.1007/s00415-018-9117-z. Epub 2018 Nov 16.

PMID:
30446966
38.

Vitiligo after alemtuzumab treatment: Secondary autoimmunity is not all about B cells.

Ruck T, Pfeuffer S, Schulte-Mecklenbeck A, Gross CC, Lindner M, Metze D, Ehrchen J, Sondermann W, Pul R, Kleinschnitz C, Wiendl H, Meuth SG, Klotz L.

Neurology. 2018 Dec 11;91(24):e2233-e2237. doi: 10.1212/WNL.0000000000006648. Epub 2018 Nov 7.

39.

Differential capability of metabolic substrates to promote hepatocellular lipid accumulation.

Hoang NA, Richter F, Schubert M, Lorkowski S, Klotz LO, Steinbrenner H.

Eur J Nutr. 2018 Oct 27. doi: 10.1007/s00394-018-1847-2. [Epub ahead of print]

PMID:
30368556
40.

Correction to: Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials.

Schultz NM, Shore ND, Chowdhury S, Klotz LH, Concepcion RS, Penson DF, Karsh LI, Yang H, Brown BA, Barlev A, Flanders SC.

BMC Urol. 2018 Oct 1;18(1):84. doi: 10.1186/s12894-018-0397-5.

41.

Nuclear trapping of inactive FOXO1 by the Nrf2 activator diethyl maleate.

Gille A, Turkistani A, Tsitsipatis D, Hou X, Tauber S, Hamann I, Urban N, Erler K, Steinbrenner H, Klotz LO.

Redox Biol. 2019 Jan;20:19-27. doi: 10.1016/j.redox.2018.09.010. Epub 2018 Sep 14.

42.
43.

The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation.

Ouellet V, Aprikian A, Bergeron A, Brimo F, Bristow RG, Chevalier S, Drachenberg D, Fazli L, Fleshner NE, Gleave M, Karakiewicz P, Klotz L, Lacombe L, Lattouf JB, van der Kwast T, Squire JA, Latour M, Trudel D, Mes-Masson AM, Saad F.

BMC Urol. 2018 Sep 10;18(1):78. doi: 10.1186/s12894-018-0392-x.

44.

Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials.

Schultz NM, Shore ND, Chowdhury S, Klotz LH, Concepcion RS, Penson DF, Karsh LI, Yang H, Brown BA, Barlev A, Flanders SC.

BMC Urol. 2018 Sep 6;18(1):77. doi: 10.1186/s12894-018-0387-7. Erratum in: BMC Urol. 2018 Oct 1;18(1):84.

45.

Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations.

Crawford ED, Heidenreich A, Lawrentschuk N, Tombal B, Pompeo ACL, Mendoza-Valdes A, Miller K, Debruyne FMJ, Klotz L.

Prostate Cancer Prostatic Dis. 2019 Mar;22(1):24-38. doi: 10.1038/s41391-018-0079-0. Epub 2018 Aug 21. Review.

46.

Discriminative power of intra-retinal layers in early multiple sclerosis using 3D OCT imaging.

Seitz CB, Droby A, Zaubitzer L, Krämer J, Paradis M, Klotz L, Wiendl H, Groppa S, Meuth SG, Zipp F, Fleischer V.

J Neurol. 2018 Oct;265(10):2284-2294. doi: 10.1007/s00415-018-8988-3. Epub 2018 Aug 2.

PMID:
30073502
47.

Nur77 serves as a molecular brake of the metabolic switch during T cell activation to restrict autoimmunity.

Liebmann M, Hucke S, Koch K, Eschborn M, Ghelman J, Chasan AI, Glander S, Schädlich M, Kuhlencord M, Daber NM, Eveslage M, Beyer M, Dietrich M, Albrecht P, Stoll M, Busch KB, Wiendl H, Roth J, Kuhlmann T, Klotz L.

Proc Natl Acad Sci U S A. 2018 Aug 21;115(34):E8017-E8026. doi: 10.1073/pnas.1721049115. Epub 2018 Aug 2.

48.

Immune Cell Profiling During Switching from Natalizumab to Fingolimod Reveals Differential Effects on Systemic Immune-Regulatory Networks and on Trafficking of Non-T Cell Populations into the Cerebrospinal Fluid-Results from the ToFingo Successor Study.

Lohmann L, Janoschka C, Schulte-Mecklenbeck A, Klinsing S, Kirstein L, Hanning U, Wirth T, Schneider-Hohendorf T, Schwab N, Gross CC, Eveslage M, Meuth SG, Wiendl H, Klotz L.

Front Immunol. 2018 Jul 9;9:1560. doi: 10.3389/fimmu.2018.01560. eCollection 2018.

49.

Furosemide and Albumin for Diuresis of Edema (FADE): A parallel-group, blinded, pilot randomized controlled trial.

Oczkowski SJW, Klotz L, Mazzetti I, Alshamsi F, Chen ML, Foster G, Meade MO, Hamielec C.

J Crit Care. 2018 Dec;48:462-467. doi: 10.1016/j.jcrc.2018.07.020. Epub 2018 Jul 19.

PMID:
30037660
50.

Oncologic and Functional Outcomes of Partial Gland Ablation with High Intensity Focused Ultrasound for Localized Prostate Cancer.

Bass R, Fleshner N, Finelli A, Barkin J, Zhang L, Klotz L.

J Urol. 2019 Jan;201(1):113-119. doi: 10.1016/j.juro.2018.07.040.

PMID:
30036514

Supplemental Content

Support Center